JP7153069B2 - ロルラチニブ遊離塩基水和物の結晶形態 - Google Patents

ロルラチニブ遊離塩基水和物の結晶形態 Download PDF

Info

Publication number
JP7153069B2
JP7153069B2 JP2020520115A JP2020520115A JP7153069B2 JP 7153069 B2 JP7153069 B2 JP 7153069B2 JP 2020520115 A JP2020520115 A JP 2020520115A JP 2020520115 A JP2020520115 A JP 2020520115A JP 7153069 B2 JP7153069 B2 JP 7153069B2
Authority
JP
Japan
Prior art keywords
ppm
theta
free base
crystalline form
base hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020520115A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020536893A (ja
JP2020536893A5 (enExample
Inventor
ボウルズ，ポール
ローズ，ピーター・ロバート
Original Assignee
ファイザー・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64049474&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7153069(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ファイザー・インク filed Critical ファイザー・インク
Publication of JP2020536893A publication Critical patent/JP2020536893A/ja
Publication of JP2020536893A5 publication Critical patent/JP2020536893A5/ja
Application granted granted Critical
Publication of JP7153069B2 publication Critical patent/JP7153069B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2020520115A 2017-10-10 2018-10-04 ロルラチニブ遊離塩基水和物の結晶形態 Active JP7153069B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762570326P 2017-10-10 2017-10-10
US62/570,326 2017-10-10
US201862727734P 2018-09-06 2018-09-06
US62/727,734 2018-09-06
PCT/IB2018/057735 WO2019073347A1 (en) 2017-10-10 2018-10-04 CRYSTALLINE BASE FREE HYDRATE SHAPE OF LORLATINIB

Publications (3)

Publication Number Publication Date
JP2020536893A JP2020536893A (ja) 2020-12-17
JP2020536893A5 JP2020536893A5 (enExample) 2021-05-27
JP7153069B2 true JP7153069B2 (ja) 2022-10-13

Family

ID=64049474

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020520115A Active JP7153069B2 (ja) 2017-10-10 2018-10-04 ロルラチニブ遊離塩基水和物の結晶形態

Country Status (21)

Country Link
US (1) US11299500B2 (enExample)
EP (1) EP3694863B1 (enExample)
JP (1) JP7153069B2 (enExample)
KR (1) KR102424621B1 (enExample)
CN (1) CN111201235B (enExample)
AU (1) AU2018349259B2 (enExample)
CA (1) CA3077508C (enExample)
CY (1) CY1126141T1 (enExample)
DK (1) DK3694863T3 (enExample)
ES (1) ES2952985T3 (enExample)
FI (1) FI3694863T3 (enExample)
HU (1) HUE062926T2 (enExample)
MX (1) MX2020003373A (enExample)
PL (1) PL3694863T3 (enExample)
PT (1) PT3694863T (enExample)
RU (1) RU2022109286A (enExample)
SG (1) SG11202002445SA (enExample)
SI (1) SI3694863T1 (enExample)
TW (1) TWI775960B (enExample)
WO (1) WO2019073347A1 (enExample)
ZA (1) ZA202001661B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3798222T3 (fi) 2015-07-31 2023-11-28 Pfizer Lorlatinibin vapaan emäksen kidemuoto
ES2819676T3 (es) 2016-04-08 2021-04-19 Pfizer Formas cristalinas de maleato de lorlatinib
WO2019209633A1 (en) * 2018-04-23 2019-10-31 Pliva Hrvatska D.O.O. Solid state forms of lorlatinib and their preparation
EP3999514A1 (en) 2019-07-18 2022-05-25 Pliva Hrvatska D.O.O. Crystalline lorlatinib : fumaric acid and solid state form thereof
CN112321604A (zh) * 2019-08-05 2021-02-05 华东理工大学 大环类jak2抑制剂及其应用
EP4041396A1 (en) 2019-10-10 2022-08-17 Sandoz AG Polymorph of lorlatinib
CN112824417A (zh) * 2019-11-21 2021-05-21 上海天慈国际药业有限公司 一种劳拉替尼的制备方法
WO2021176349A1 (en) 2020-03-05 2021-09-10 Pfizer Inc. Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor
CN111362967B (zh) * 2020-04-28 2021-09-07 南京雷正医药科技有限公司 苯并氧杂二氮杂十四碳烯衍生物及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015010091A (ja) 2013-06-28 2015-01-19 ファイザー・インク 大環状キナーゼ阻害剤の固体形態
JP2015510879A (ja) 2012-03-06 2015-04-13 ファイザー・インク 増殖性疾患の治療のための大環状誘導体
JP2017039702A (ja) 2015-07-31 2017-02-23 ファイザー・インク ロルラチニブ遊離塩基の結晶形態

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916593B2 (en) 2010-05-04 2014-12-23 Pfizer Inc. Alkoxy-substituted 2-aminopyridines as ALK inhibitors
WO2012121764A1 (en) 2010-11-25 2012-09-13 Ratiopharm Gmbh Novel salts and polymorphic forms of afatinib
MX355421B (es) 2011-06-08 2018-04-18 Biogen Ma Inc Proceso para preparar fumarato de dimetilo cristalino y de alta pureza.
WO2016026423A1 (en) * 2014-08-20 2016-02-25 Teligene Ltd Substituted macrocycles useful as kinases inhibitors and methods of use thereof
EP3183256A4 (en) * 2014-08-20 2018-05-30 Teligene Ltd. Substituted macrocycles useful as kinases inhibitors and methods of use thereof
ES2819676T3 (es) 2016-04-08 2021-04-19 Pfizer Formas cristalinas de maleato de lorlatinib

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015510879A (ja) 2012-03-06 2015-04-13 ファイザー・インク 増殖性疾患の治療のための大環状誘導体
JP2015010091A (ja) 2013-06-28 2015-01-19 ファイザー・インク 大環状キナーゼ阻害剤の固体形態
JP2017039702A (ja) 2015-07-31 2017-02-23 ファイザー・インク ロルラチニブ遊離塩基の結晶形態

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Pharm Thec Japan，2002年，18(10)，P.1629-1644
Pharma Stage，2007年，6(10)，P.48-53

Also Published As

Publication number Publication date
RU2020113141A3 (enExample) 2021-11-12
MX2020003373A (es) 2020-10-12
TWI775960B (zh) 2022-09-01
BR112020005989A2 (pt) 2020-09-29
EP3694863A1 (en) 2020-08-19
ES2952985T3 (es) 2023-11-07
CY1126141T1 (el) 2023-11-15
CN111201235A (zh) 2020-05-26
US20200308191A1 (en) 2020-10-01
CA3077508A1 (en) 2019-04-18
JP2020536893A (ja) 2020-12-17
AU2018349259A1 (en) 2020-04-09
RU2022109286A (ru) 2022-05-06
AU2018349259B2 (en) 2021-02-18
HUE062926T2 (hu) 2023-12-28
SI3694863T1 (sl) 2023-10-30
RU2020113141A (ru) 2021-11-12
EP3694863B1 (en) 2023-06-21
CN111201235B (zh) 2023-02-10
FI3694863T3 (fi) 2023-08-18
PT3694863T (pt) 2023-08-23
CA3077508C (en) 2023-02-14
TW201922753A (zh) 2019-06-16
KR20200051781A (ko) 2020-05-13
WO2019073347A1 (en) 2019-04-18
DK3694863T3 (da) 2023-07-03
US11299500B2 (en) 2022-04-12
KR102424621B1 (ko) 2022-07-25
ZA202001661B (en) 2023-11-29
SG11202002445SA (en) 2020-04-29
PL3694863T3 (pl) 2023-09-25

Similar Documents

Publication Publication Date Title
JP7153069B2 (ja) ロルラチニブ遊離塩基水和物の結晶形態
US11020376B2 (en) Crystalline form of lorlatinib free base
CA3019905C (en) Crystalline forms of lorlatinib maleate
RU2845218C2 (ru) Кристаллическая форма гидрата свободного основания лорлатиниба
HK40029499B (en) Crystalline form of lorlatinib free base hydrate
HK40029499A (en) Crystalline form of lorlatinib free base hydrate
BR112020005989B1 (pt) Forma cristalina de hidrato de base livre de lorlatinibe, composição e usos

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210416

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210416

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220311

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220711

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220916

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220930

R150 Certificate of patent or registration of utility model

Ref document number: 7153069

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250